Patent: 10,342,869
✉ Email this page to a colleague
Summary for Patent: 10,342,869
| Title: | Compositions comprising anti-CD38 antibodies and lenalidomide |
| Abstract: | Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits. |
| Inventor(s): | Byron C. Hann, Blake Tomkinson, Thomas G. Martin, III, Blake T. Aftab |
| Assignee: | Sanofi Aventis US LLC , University of California San Diego UCSD |
| Application Number: | US14/098,710 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,342,869
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 23-Nov-04 | 10,342,869 | 2033-12-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,342,869
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 093844 | ⤷ Start Trial |
| Australia | 2013355064 | ⤷ Start Trial |
| Australia | 2018211258 | ⤷ Start Trial |
| Brazil | 112015012987 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
